AREG and colorectal carcinoma: Low expression of EGFR or its key low-affinity ligands, amphiregulin (AREG) and epiregulin (EREG) causes loss of target for anti-EGFR therapy in CRC (Jacobs et al., 2009; Seligmann et al., 2016).